Where does SignalRx Pharmaceuticals, Inc. rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), SignalRx Pharmaceuticals, Inc. ranks #37,534 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does SignalRx Pharmaceuticals, Inc. hold?

SignalRx Pharmaceuticals, Inc. holds 7 US utility patents granted between 2016 and 2023, spanning 5 technology areas.

What is SignalRx Pharmaceuticals, Inc.'s Innovation Score?

SignalRx Pharmaceuticals, Inc. has an Innovation Score of 25.5 out of 100 (18th percentile of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

What technology areas does SignalRx Pharmaceuticals, Inc. focus on?

SignalRx Pharmaceuticals, Inc.'s top technology area is C07D (Heterocyclic Compounds) with 7 patents, ranking #1,096 of 3,165 assignees active in that subclass. Grants appear in 5 CPC subclasses total.

Is SignalRx Pharmaceuticals, Inc.'s patent grant rate increasing or decreasing?

SignalRx Pharmaceuticals, Inc.'s recent grant velocity is -60% compared to the prior five-year period (grant years, not application filing dates). Grant activity has slowed relative to earlier years.

What does claim depth mean for SignalRx Pharmaceuticals, Inc.'s patents?

SignalRx Pharmaceuticals, Inc.'s patents average 6.3 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the SignalRx Pharmaceuticals, Inc. patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView US Corporation

SignalRx Pharmaceuticals, Inc.

USPTO PatentsView assignee record - 7 granted patents across 5 technology areas, recorded in grant years 2016–2023. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: C07D (Heterocyclic Compounds).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Signalrx ranks #37,534 of 49,997 tracked US assignees by granted-patent volume, with 7 patents across 5 technology areas.

#37,534
of 49,997 US assignees by volume: 18th percentile
by Innovation Score (25.5/100): 6.3
avg claims per patent: -60%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R37534 · US Corporation #37,534 · 7 grants

GRANTS-MICRO · LOWER-Q · PHOTO-FINISH · CPC-NARROW · INNOV-THIN · CLAIMS-SPARSE · TYPE-USCORP · VEL-DROP · BOOK-FULL

GRANTS-MICRO 7 grants
LOWER-Q #37,534/49,997
PHOTO-FINISH Siematic Möbelwerke…
CPC-NARROW C07D · 5 areas
INNOV-THIN 25.5/100
CLAIMS-SPARSE 6.3 claims/avg
TYPE-USCORP US Corporation
VEL-DROP -60% vel
BOOK-FULL 10/10 fields

Nearest grant-volume peer: Siematic Möbelwerke GmbH & Co. KG (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How Signalrx’s 25.5 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Volume 7.2 pts (28%) Velocity 6.7 pts (26%) Breadth 7.9 pts (31%) Claim depth 3.8 pts (15%)

Qualcomm Incorporated · highest

85
SignalRx Pharmaceuti… · this assignee

26
3D Lighting… · lowest

7

What this shows Signalrx's Innovation Score is 25.5/100 (18th percentile of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Does more volume mean deeper claims for Signalrx?

Each dot is one of Signalrx’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Signalrx’s own 6.3 claims/patent is at or below the 14.9 median for these volume peers. Volume here does not track with deeper claims; several lower-volume peers claim more thoroughly per patent.

Signalrx vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where Signalrx's grants concentrate

SignalRx Pharmaceuticals, Inc. is a focused PatentsView assignee: 5 CPC subclasses with 100% of grants classified under C07D (Heterocyclic Compounds). Peak complete grant year is 2019 (2 grants) versus a trough of 1 in 2016. By volume, Signalrx sits between Siematic Möbelwerke GmbH & Co. KG and Silicon Beach Media II, Inc..

Signalrx's three-year grant acceleration

SignalRx Pharmaceuticals, Inc. shows 2 grants in 2022–2024 against only 2 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

Siematic Möbelwer…

7
Siemens Mobility…

7
Sierra Pacific In…

7
Signal Solutions

7
Signifier Medical

7
Silgan Dispensing…

7
Silgan Dispensing…

7
Silicon Beach Med…

7
Signalrx Pharmace… ◀

7

What this shows SignalRx holds 7 patents at rank #37,631, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near SignalRx

By rank, the assignees closest to #37,631 in granted patent volume.

Leaders in C07D (Heterocyclic Compounds)

Other assignees with the most granted patents in SignalRx's primary technology class.

Signalrx's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

26 18th percentile higher than 18% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2016–2023

Grants by year

Teal-shaded recent years (2020–present) versus the 2016–2019 baseline. Full figures in the table below.

View data table

SignalRx Pharmaceuticals, Inc. patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2016	1	14.3%
2017	1	14.3%
2018	1	14.3%
2019	2	28.6%
2022	1	14.3%
2023	1	14.3%

Which technologies does SignalRx Pharmaceuticals, Inc. patent most?

C07D - Heterocyclic Compounds 7

A61K - Preparations FOR Medical, Dental OR Toiletry Purposes 6

A61P - Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations 4

C07K - Peptides 2

C07F - Acyclic, Carbocyclic OR Heterocyclic Compounds Containing Elements Other Than Carbon, Hydrogen, Halogen, Oxygen, Nitrogen, Sulfur, Selenium OR Tellurium 2

Top 5 of 5 technology areas

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

View all rankings → How is Innovation Score calculated?

What to do with this data

SignalRx Pharmaceuticals, Inc.'s patent record in context - here's where to go next.

SignalRx Pharmaceuticals, Inc.'s lead technology class is C07D (Heterocyclic Compounds), 100% of its portfolio - see every assignee active in that class. Explore C07D
Ranked #37,534 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare SignalRx Pharmaceuticals, Inc. against Siematic Möbelwerke GmbH & Co. KG, an assignee filing at a similar volume. Compare portfolios
Innovation Score of 25.5/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent , US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.